A network meta-analysis of the association between patient traits and response to regular dosing with ICS plus short-acting β2-agonist reliever or ICS/formoterol reliever only in mild asthma

Simple item page
dc.contributor.authorYorgancıoğlu A.
dc.contributor.authorCruz A.A.
dc.contributor.authorGarcia G.
dc.contributor.authorLavoie K.L.
dc.contributor.authorRoche N.
dc.contributor.authorVerma M.
dc.contributor.authorMajumdar A.
dc.contributor.authorChatterjee S.
dc.date.accessioned2024-07-22T08:01:24Z
dc.date.available2024-07-22T08:01:24Z
dc.date.issued2024
dc.description.abstractIntroduction/background: Mild asthma treatment recommendations include intermittent inhaled corticosteroid (ICS)/formoterol dosing or regular ICS dosing with short-acting β2-agonist reliever. Due to the heterogeneity of asthma, identification of traits associated with improved outcomes to specific treatments would be clinically beneficial. Aims/objectives: To assess the impact of patient traits on treatment outcomes of regular ICS dosing compared with intermittent ICS/formoterol dosing, a systematic literature review (SLR) and network meta-analysis (NMA) was conducted. Searches identified randomised controlled trials (RCTs) of patients with asthma aged ≥12 years, containing ≥1 regular ICS dosing or intermittent ICS/formoterol dosing treatment arm, reporting traits and outcomes of interest. Results: The SLR identified 11 RCTs of mild asthma, of 14,516 patients. A total of 11 traits and 11 outcomes of interest were identified. Of these, a feasibility assessment indicated possible assessment of three traits (age, baseline lung function, smoking history) and two outcomes (exacerbation rate, change in lung function). The NMA found no significant association of any trait with any outcome with regular ICS dosing relative to intermittent ICS/formoterol dosing. Inconsistent reporting of traits and outcomes between RCTs limited analysis. Conclusions: This is the first systematic analysis of associations between patient traits and differential treatment outcomes in mild asthma. Although the traits analysed were not found to significantly interact with relative treatment response, inconsistent reporting from the RCTs prevented assessment of some of the most clinically relevant traits and outcomes, such as adherence. More consistent reporting of respiratory RCTs would provide more comparable data and aid future analyses. © 2024
dc.identifier.DOI-ID10.1016/j.rmed.2024.107610
dc.identifier.issn09546111
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11441
dc.language.isoEnglish
dc.publisherW.B. Saunders Ltd
dc.subjectAdministration, Inhalation
dc.subjectAdolescent
dc.subjectAdrenal Cortex Hormones
dc.subjectAdrenergic beta-2 Receptor Agonists
dc.subjectAdult
dc.subjectAge Factors
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectFormoterol Fumarate
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNetwork Meta-Analysis
dc.subjectRandomized Controlled Trials as Topic
dc.subjectSmoking
dc.subjectTreatment Outcome
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectformoterol
dc.subjectantiasthmatic agent
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectformoterol fumarate
dc.subjectArticle
dc.subjectchild
dc.subjectclinical outcome
dc.subjectcontrolled clinical trial (topic)
dc.subjectdisease exacerbation
dc.subjectforced expiratory volume
dc.subjecthuman
dc.subjectlung function
dc.subjectmaintenance therapy
dc.subjectnetwork meta-analysis
dc.subjectoutcome assessment
dc.subjectpractice guideline
dc.subjectsevere asthma
dc.subjectsmoking
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectadolescent
dc.subjectadult
dc.subjectage
dc.subjectasthma
dc.subjectcombination drug therapy
dc.subjectfemale
dc.subjectinhalational drug administration
dc.subjectmale
dc.subjectmeta analysis
dc.subjectmiddle aged
dc.subjectrandomized controlled trial (topic)
dc.titleA network meta-analysis of the association between patient traits and response to regular dosing with ICS plus short-acting β2-agonist reliever or ICS/formoterol reliever only in mild asthma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu